Please assess the completion status of the following clinical trial:

Trial Title: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects chronically infected with HCV genotype 1 (Phase 2a and Phase 2b)~* Subjects chronically infected with HCV genotype 4 (Phase 2b only)~* HCV RNA viral load of ≥ 10\*5\* IU/mL at screening~* BMI of 18 - 35 kg/m² at screening~Exclusion Criteria:~* Cirrhosis (Phase 2a only)~* Decompensated cirrhosis (Phase 2b)~* Co-infection with HBV or HIV~* Hepatocellular carcinoma~* Prior treatment with anti-HCV drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2a: Arm 1 (Type: EXPERIMENTAL): None
- Phase 2a: Arm 2 (Type: PLACEBO_COMPARATOR): None
- Phase 2b: Arm 1 (Type: EXPERIMENTAL): None
- Phase 2b: Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).